BioNTech
BNTX
80.96
-0.42
-0.52%
BioNTech
US · BNTX
#801 by market cap
Listed 2019
80.96
-0.42
-0.52%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About BioNTech
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
- Founded
- 2008
- CEO
- Professor Ugur Sahin, M.D.
- Employees
- 7,807
- Headquarters
- Mainz, Rheinland-Pfalz, Germany
- Fiscal year end
- 12-31
- Website
- biontech.de
Company profile
- Exchange
- US
- Symbol
- BNTX
- Market-cap rank
- #801
- Listing date
- 2019-10-10
- Market cap
- 20.07B
- Float cap
- 8.58B
- Shares out
- 247.93M
- Float shares
- 106.00M
Sectors & themes
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BioNTech discussion 0 comments